You are here: / / Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From...

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

/in ,

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

2012 AACR: SGI-110, a novel SQ second generation DNA hypomethylating agent2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in...